0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cell and Gene Therapy CDMO Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-22A15350
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Cell and Gene Therapy CDMO Market Research Report 2023
BUY CHAPTERS

Global Cell and Gene Therapy CDMO Market Research Report 2025

Code: QYRE-Auto-22A15350
Report
May 2025
Pages:94
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Cell and Gene Therapy CDMO Market

The global market for Cell and Gene Therapy CDMO was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Cell and Gene Therapy CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Cell and Gene Therapy CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Cell and Gene Therapy CDMO in Pharmaceutical Company is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Cell and Gene Therapy CDMO include Lonza, Charles River Laboratories, Cytiva, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, BioCentriq, RoslinCT, Thermo Scientific, Mesoblast, Cellularity, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cell and Gene Therapy CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell and Gene Therapy CDMO.
The Cell and Gene Therapy CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cell and Gene Therapy CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cell and Gene Therapy CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Cell and Gene Therapy CDMO Market Report

Report Metric Details
Report Name Cell and Gene Therapy CDMO Market
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Lonza, Charles River Laboratories, Cytiva, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, BioCentriq, RoslinCT, Thermo Scientific, Mesoblast, Cellularity, Bluebird Bio, Editas Medicine, Andelyn Biosciences, Wuxi Advanced Therapies, AGC Biologics, Pfizer CentreOne, Almac Group, PCI Pharma Services
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Cell and Gene Therapy CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cell and Gene Therapy CDMO Market report?

Ans: The main players in the Cell and Gene Therapy CDMO Market are Lonza, Charles River Laboratories, Cytiva, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, BioCentriq, RoslinCT, Thermo Scientific, Mesoblast, Cellularity, Bluebird Bio, Editas Medicine, Andelyn Biosciences, Wuxi Advanced Therapies, AGC Biologics, Pfizer CentreOne, Almac Group, PCI Pharma Services

What are the Application segmentation covered in the Cell and Gene Therapy CDMO Market report?

Ans: The Applications covered in the Cell and Gene Therapy CDMO Market report are Pharmaceutical Company, Biotechnology Company, Other

What are the Type segmentation covered in the Cell and Gene Therapy CDMO Market report?

Ans: The Types covered in the Cell and Gene Therapy CDMO Market report are Clinical Trial Material CDMOs, Development and Manufacturing CDMOs, Other

Recommended Reports

CDMO Services

Gene Therapy Products

Cell Therapy Manufacturing

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell and Gene Therapy CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Clinical Trial Material CDMOs
1.2.3 Development and Manufacturing CDMOs
1.2.4 Other
1.3 Market by Application
1.3.1 Global Cell and Gene Therapy CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell and Gene Therapy CDMO Market Perspective (2020-2031)
2.2 Global Cell and Gene Therapy CDMO Growth Trends by Region
2.2.1 Global Cell and Gene Therapy CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Cell and Gene Therapy CDMO Historic Market Size by Region (2020-2025)
2.2.3 Cell and Gene Therapy CDMO Forecasted Market Size by Region (2026-2031)
2.3 Cell and Gene Therapy CDMO Market Dynamics
2.3.1 Cell and Gene Therapy CDMO Industry Trends
2.3.2 Cell and Gene Therapy CDMO Market Drivers
2.3.3 Cell and Gene Therapy CDMO Market Challenges
2.3.4 Cell and Gene Therapy CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell and Gene Therapy CDMO Players by Revenue
3.1.1 Global Top Cell and Gene Therapy CDMO Players by Revenue (2020-2025)
3.1.2 Global Cell and Gene Therapy CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Cell and Gene Therapy CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cell and Gene Therapy CDMO Revenue
3.4 Global Cell and Gene Therapy CDMO Market Concentration Ratio
3.4.1 Global Cell and Gene Therapy CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell and Gene Therapy CDMO Revenue in 2024
3.5 Global Key Players of Cell and Gene Therapy CDMO Head office and Area Served
3.6 Global Key Players of Cell and Gene Therapy CDMO, Product and Application
3.7 Global Key Players of Cell and Gene Therapy CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell and Gene Therapy CDMO Breakdown Data by Type
4.1 Global Cell and Gene Therapy CDMO Historic Market Size by Type (2020-2025)
4.2 Global Cell and Gene Therapy CDMO Forecasted Market Size by Type (2026-2031)
5 Cell and Gene Therapy CDMO Breakdown Data by Application
5.1 Global Cell and Gene Therapy CDMO Historic Market Size by Application (2020-2025)
5.2 Global Cell and Gene Therapy CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Cell and Gene Therapy CDMO Market Size (2020-2031)
6.2 North America Cell and Gene Therapy CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Cell and Gene Therapy CDMO Market Size by Country (2020-2025)
6.4 North America Cell and Gene Therapy CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cell and Gene Therapy CDMO Market Size (2020-2031)
7.2 Europe Cell and Gene Therapy CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Cell and Gene Therapy CDMO Market Size by Country (2020-2025)
7.4 Europe Cell and Gene Therapy CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell and Gene Therapy CDMO Market Size (2020-2031)
8.2 Asia-Pacific Cell and Gene Therapy CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cell and Gene Therapy CDMO Market Size (2020-2031)
9.2 Latin America Cell and Gene Therapy CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Cell and Gene Therapy CDMO Market Size by Country (2020-2025)
9.4 Latin America Cell and Gene Therapy CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell and Gene Therapy CDMO Market Size (2020-2031)
10.2 Middle East & Africa Cell and Gene Therapy CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Cell and Gene Therapy CDMO Introduction
11.1.4 Lonza Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.1.5 Lonza Recent Development
11.2 Charles River Laboratories
11.2.1 Charles River Laboratories Company Details
11.2.2 Charles River Laboratories Business Overview
11.2.3 Charles River Laboratories Cell and Gene Therapy CDMO Introduction
11.2.4 Charles River Laboratories Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.2.5 Charles River Laboratories Recent Development
11.3 Cytiva
11.3.1 Cytiva Company Details
11.3.2 Cytiva Business Overview
11.3.3 Cytiva Cell and Gene Therapy CDMO Introduction
11.3.4 Cytiva Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.3.5 Cytiva Recent Development
11.4 Catalent Biologics
11.4.1 Catalent Biologics Company Details
11.4.2 Catalent Biologics Business Overview
11.4.3 Catalent Biologics Cell and Gene Therapy CDMO Introduction
11.4.4 Catalent Biologics Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.4.5 Catalent Biologics Recent Development
11.5 FUJIFILM Diosynth Biotechnologies
11.5.1 FUJIFILM Diosynth Biotechnologies Company Details
11.5.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.5.3 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Introduction
11.5.4 FUJIFILM Diosynth Biotechnologies Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.5.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.6 BioCentriq
11.6.1 BioCentriq Company Details
11.6.2 BioCentriq Business Overview
11.6.3 BioCentriq Cell and Gene Therapy CDMO Introduction
11.6.4 BioCentriq Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.6.5 BioCentriq Recent Development
11.7 RoslinCT
11.7.1 RoslinCT Company Details
11.7.2 RoslinCT Business Overview
11.7.3 RoslinCT Cell and Gene Therapy CDMO Introduction
11.7.4 RoslinCT Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.7.5 RoslinCT Recent Development
11.8 Thermo Scientific
11.8.1 Thermo Scientific Company Details
11.8.2 Thermo Scientific Business Overview
11.8.3 Thermo Scientific Cell and Gene Therapy CDMO Introduction
11.8.4 Thermo Scientific Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.8.5 Thermo Scientific Recent Development
11.9 Mesoblast
11.9.1 Mesoblast Company Details
11.9.2 Mesoblast Business Overview
11.9.3 Mesoblast Cell and Gene Therapy CDMO Introduction
11.9.4 Mesoblast Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.9.5 Mesoblast Recent Development
11.10 Cellularity
11.10.1 Cellularity Company Details
11.10.2 Cellularity Business Overview
11.10.3 Cellularity Cell and Gene Therapy CDMO Introduction
11.10.4 Cellularity Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.10.5 Cellularity Recent Development
11.11 Bluebird Bio
11.11.1 Bluebird Bio Company Details
11.11.2 Bluebird Bio Business Overview
11.11.3 Bluebird Bio Cell and Gene Therapy CDMO Introduction
11.11.4 Bluebird Bio Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.11.5 Bluebird Bio Recent Development
11.12 Editas Medicine
11.12.1 Editas Medicine Company Details
11.12.2 Editas Medicine Business Overview
11.12.3 Editas Medicine Cell and Gene Therapy CDMO Introduction
11.12.4 Editas Medicine Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.12.5 Editas Medicine Recent Development
11.13 Andelyn Biosciences
11.13.1 Andelyn Biosciences Company Details
11.13.2 Andelyn Biosciences Business Overview
11.13.3 Andelyn Biosciences Cell and Gene Therapy CDMO Introduction
11.13.4 Andelyn Biosciences Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.13.5 Andelyn Biosciences Recent Development
11.14 Wuxi Advanced Therapies
11.14.1 Wuxi Advanced Therapies Company Details
11.14.2 Wuxi Advanced Therapies Business Overview
11.14.3 Wuxi Advanced Therapies Cell and Gene Therapy CDMO Introduction
11.14.4 Wuxi Advanced Therapies Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.14.5 Wuxi Advanced Therapies Recent Development
11.15 AGC Biologics
11.15.1 AGC Biologics Company Details
11.15.2 AGC Biologics Business Overview
11.15.3 AGC Biologics Cell and Gene Therapy CDMO Introduction
11.15.4 AGC Biologics Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.15.5 AGC Biologics Recent Development
11.16 Pfizer CentreOne
11.16.1 Pfizer CentreOne Company Details
11.16.2 Pfizer CentreOne Business Overview
11.16.3 Pfizer CentreOne Cell and Gene Therapy CDMO Introduction
11.16.4 Pfizer CentreOne Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.16.5 Pfizer CentreOne Recent Development
11.17 Almac Group
11.17.1 Almac Group Company Details
11.17.2 Almac Group Business Overview
11.17.3 Almac Group Cell and Gene Therapy CDMO Introduction
11.17.4 Almac Group Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.17.5 Almac Group Recent Development
11.18 PCI Pharma Services
11.18.1 PCI Pharma Services Company Details
11.18.2 PCI Pharma Services Business Overview
11.18.3 PCI Pharma Services Cell and Gene Therapy CDMO Introduction
11.18.4 PCI Pharma Services Revenue in Cell and Gene Therapy CDMO Business (2020-2025)
11.18.5 PCI Pharma Services Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Cell and Gene Therapy CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Clinical Trial Material CDMOs
 Table 3. Key Players of Development and Manufacturing CDMOs
 Table 4. Key Players of Other
 Table 5. Global Cell and Gene Therapy CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Cell and Gene Therapy CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Cell and Gene Therapy CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Cell and Gene Therapy CDMO Market Share by Region (2020-2025)
 Table 9. Global Cell and Gene Therapy CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Cell and Gene Therapy CDMO Market Share by Region (2026-2031)
 Table 11. Cell and Gene Therapy CDMO Market Trends
 Table 12. Cell and Gene Therapy CDMO Market Drivers
 Table 13. Cell and Gene Therapy CDMO Market Challenges
 Table 14. Cell and Gene Therapy CDMO Market Restraints
 Table 15. Global Cell and Gene Therapy CDMO Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Cell and Gene Therapy CDMO Market Share by Players (2020-2025)
 Table 17. Global Top Cell and Gene Therapy CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell and Gene Therapy CDMO as of 2024)
 Table 18. Ranking of Global Top Cell and Gene Therapy CDMO Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Cell and Gene Therapy CDMO Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Cell and Gene Therapy CDMO, Headquarters and Area Served
 Table 21. Global Key Players of Cell and Gene Therapy CDMO, Product and Application
 Table 22. Global Key Players of Cell and Gene Therapy CDMO, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Cell and Gene Therapy CDMO Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Cell and Gene Therapy CDMO Revenue Market Share by Type (2020-2025)
 Table 26. Global Cell and Gene Therapy CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Cell and Gene Therapy CDMO Revenue Market Share by Type (2026-2031)
 Table 28. Global Cell and Gene Therapy CDMO Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Cell and Gene Therapy CDMO Revenue Market Share by Application (2020-2025)
 Table 30. Global Cell and Gene Therapy CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Cell and Gene Therapy CDMO Revenue Market Share by Application (2026-2031)
 Table 32. North America Cell and Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Cell and Gene Therapy CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Cell and Gene Therapy CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Cell and Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Cell and Gene Therapy CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Cell and Gene Therapy CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Cell and Gene Therapy CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Cell and Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Cell and Gene Therapy CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Cell and Gene Therapy CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Cell and Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Lonza Company Details
 Table 48. Lonza Business Overview
 Table 49. Lonza Cell and Gene Therapy CDMO Product
 Table 50. Lonza Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 51. Lonza Recent Development
 Table 52. Charles River Laboratories Company Details
 Table 53. Charles River Laboratories Business Overview
 Table 54. Charles River Laboratories Cell and Gene Therapy CDMO Product
 Table 55. Charles River Laboratories Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 56. Charles River Laboratories Recent Development
 Table 57. Cytiva Company Details
 Table 58. Cytiva Business Overview
 Table 59. Cytiva Cell and Gene Therapy CDMO Product
 Table 60. Cytiva Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 61. Cytiva Recent Development
 Table 62. Catalent Biologics Company Details
 Table 63. Catalent Biologics Business Overview
 Table 64. Catalent Biologics Cell and Gene Therapy CDMO Product
 Table 65. Catalent Biologics Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 66. Catalent Biologics Recent Development
 Table 67. FUJIFILM Diosynth Biotechnologies Company Details
 Table 68. FUJIFILM Diosynth Biotechnologies Business Overview
 Table 69. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product
 Table 70. FUJIFILM Diosynth Biotechnologies Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 71. FUJIFILM Diosynth Biotechnologies Recent Development
 Table 72. BioCentriq Company Details
 Table 73. BioCentriq Business Overview
 Table 74. BioCentriq Cell and Gene Therapy CDMO Product
 Table 75. BioCentriq Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 76. BioCentriq Recent Development
 Table 77. RoslinCT Company Details
 Table 78. RoslinCT Business Overview
 Table 79. RoslinCT Cell and Gene Therapy CDMO Product
 Table 80. RoslinCT Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 81. RoslinCT Recent Development
 Table 82. Thermo Scientific Company Details
 Table 83. Thermo Scientific Business Overview
 Table 84. Thermo Scientific Cell and Gene Therapy CDMO Product
 Table 85. Thermo Scientific Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 86. Thermo Scientific Recent Development
 Table 87. Mesoblast Company Details
 Table 88. Mesoblast Business Overview
 Table 89. Mesoblast Cell and Gene Therapy CDMO Product
 Table 90. Mesoblast Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 91. Mesoblast Recent Development
 Table 92. Cellularity Company Details
 Table 93. Cellularity Business Overview
 Table 94. Cellularity Cell and Gene Therapy CDMO Product
 Table 95. Cellularity Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 96. Cellularity Recent Development
 Table 97. Bluebird Bio Company Details
 Table 98. Bluebird Bio Business Overview
 Table 99. Bluebird Bio Cell and Gene Therapy CDMO Product
 Table 100. Bluebird Bio Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 101. Bluebird Bio Recent Development
 Table 102. Editas Medicine Company Details
 Table 103. Editas Medicine Business Overview
 Table 104. Editas Medicine Cell and Gene Therapy CDMO Product
 Table 105. Editas Medicine Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 106. Editas Medicine Recent Development
 Table 107. Andelyn Biosciences Company Details
 Table 108. Andelyn Biosciences Business Overview
 Table 109. Andelyn Biosciences Cell and Gene Therapy CDMO Product
 Table 110. Andelyn Biosciences Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 111. Andelyn Biosciences Recent Development
 Table 112. Wuxi Advanced Therapies Company Details
 Table 113. Wuxi Advanced Therapies Business Overview
 Table 114. Wuxi Advanced Therapies Cell and Gene Therapy CDMO Product
 Table 115. Wuxi Advanced Therapies Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 116. Wuxi Advanced Therapies Recent Development
 Table 117. AGC Biologics Company Details
 Table 118. AGC Biologics Business Overview
 Table 119. AGC Biologics Cell and Gene Therapy CDMO Product
 Table 120. AGC Biologics Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 121. AGC Biologics Recent Development
 Table 122. Pfizer CentreOne Company Details
 Table 123. Pfizer CentreOne Business Overview
 Table 124. Pfizer CentreOne Cell and Gene Therapy CDMO Product
 Table 125. Pfizer CentreOne Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 126. Pfizer CentreOne Recent Development
 Table 127. Almac Group Company Details
 Table 128. Almac Group Business Overview
 Table 129. Almac Group Cell and Gene Therapy CDMO Product
 Table 130. Almac Group Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 131. Almac Group Recent Development
 Table 132. PCI Pharma Services Company Details
 Table 133. PCI Pharma Services Business Overview
 Table 134. PCI Pharma Services Cell and Gene Therapy CDMO Product
 Table 135. PCI Pharma Services Revenue in Cell and Gene Therapy CDMO Business (2020-2025) & (US$ Million)
 Table 136. PCI Pharma Services Recent Development
 Table 137. Research Programs/Design for This Report
 Table 138. Key Data Information from Secondary Sources
 Table 139. Key Data Information from Primary Sources
 Table 140. Authors List of This Report


List of Figures
 Figure 1. Cell and Gene Therapy CDMO Picture
 Figure 2. Global Cell and Gene Therapy CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Cell and Gene Therapy CDMO Market Share by Type: 2024 VS 2031
 Figure 4. Clinical Trial Material CDMOs Features
 Figure 5. Development and Manufacturing CDMOs Features
 Figure 6. Other Features
 Figure 7. Global Cell and Gene Therapy CDMO Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Cell and Gene Therapy CDMO Market Share by Application: 2024 VS 2031
 Figure 9. Pharmaceutical Company Case Studies
 Figure 10. Biotechnology Company Case Studies
 Figure 11. Other Case Studies
 Figure 12. Cell and Gene Therapy CDMO Report Years Considered
 Figure 13. Global Cell and Gene Therapy CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Cell and Gene Therapy CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Cell and Gene Therapy CDMO Market Share by Region: 2024 VS 2031
 Figure 16. Global Cell and Gene Therapy CDMO Market Share by Players in 2024
 Figure 17. Global Top Cell and Gene Therapy CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell and Gene Therapy CDMO as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Cell and Gene Therapy CDMO Revenue in 2024
 Figure 19. North America Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Cell and Gene Therapy CDMO Market Share by Country (2020-2031)
 Figure 21. United States Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Cell and Gene Therapy CDMO Market Share by Country (2020-2031)
 Figure 25. Germany Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Cell and Gene Therapy CDMO Market Share by Region (2020-2031)
 Figure 33. China Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Cell and Gene Therapy CDMO Market Share by Country (2020-2031)
 Figure 41. Mexico Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Cell and Gene Therapy CDMO Market Share by Country (2020-2031)
 Figure 45. Turkey Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Cell and Gene Therapy CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Lonza Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 49. Charles River Laboratories Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 50. Cytiva Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 51. Catalent Biologics Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 52. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 53. BioCentriq Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 54. RoslinCT Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 55. Thermo Scientific Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 56. Mesoblast Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 57. Cellularity Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 58. Bluebird Bio Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 59. Editas Medicine Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 60. Andelyn Biosciences Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 61. Wuxi Advanced Therapies Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 62. AGC Biologics Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 63. Pfizer CentreOne Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 64. Almac Group Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 65. PCI Pharma Services Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2020-2025)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

RELATED REPORTS

Global Cephalosporin APIs and Cephalosporin Intermediates Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19G16926
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global ELISA Immunoassay Plates Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-7Z17064
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Ready-to-Use ELISA Kits Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-20P20045
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Moxidectin Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3Z19977
Thu Sep 25 00:00:00 UTC 2025

Add to Cart